mice showed 20% reduction of incubation time, reduced prion protein deposition in the brain with 48 attenuated glial reactions, and reduced localization of prion proteins to lipid rafts. These results 49 raise the possibility that the gangliosides may have an important role in prion disease pathogenesis 50 by affecting the localization of prion proteins to lipid rafts. 51
INTRODUCTION 53
Prion diseases are fatal transmissible neurodegenerative diseases including Creutzfeldt-Jakob 54 disease (CJD), Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia in humans, 55 or bovine spongiform encephalopathy, chronic wasting disease, and scrapie in animals. 56 Accumulation of an abnormal protease-resistant isoform of prion protein (PrP Sc ), which is 57 generated by conformational conversion of the normal cellular isoform (PrP C ), is one of the 58 pathognomonic features of prion diseases (1) . 59 Membrane microdomains where PrP C and PrP Sc localized are lipid rafts (2) (3) (4) (5) (6) . Lipid rafts are 60 enriched in cholesterol, sphingolipids, and glycosylphosphatidylinositol (GPI)-anchored proteins 61
including PrP, and show partial resistance against mild detergent treatment (7, 8). Therefore, lipid 62 rafts buoy toward low density fractions in density gradient ultracentrifugation after mild detergent 63 treatment, namely flotation assay. Lipid rafts have been reported to serve many microorganisms 64 for infection or serve the clustering of receptors or signaling molecules to facilitate signal 65 transduction (8, 9) . In prion disease pathogenesis, the localization of PrP C and PrP Sc to lipid rafts 66 has been reported to be important for the conformational conversion (3). 67
Gangliosides are sialic acid-containing glycosphingolipids highly expressed in the brain. 68 Gangliosides are synthesized in the Golgi apparatus by specific glycosyltransferases, the 69 expression of which controls the steady-state levels of gangliosides (10). Gangliosides are 70 characterized by the number and positions of sialic acids that define their classification into A, M, 71 D, T, Q, and P (zero to five sialic acids) and a, b, and c series (one, two, or three sialic acids on 72 internal galactose residue) ( Figure 1 ). Gangliosides are embedded in the outer layer of the plasma 73 membrane and one of major components of lipid rafts (7) . Therefore, alteration in the ganglioside 74 composition of lipid rafts can affect the localization of lipid raft-associated proteins (11-13). For 75 example, knock-out (KO) mice lacking GD2/GM2 synthase, in which GA2, GM2, GD2, GT2, 76 5 and downstream gangliosides are depleted, show the dispersion of lipid raft-associated proteins 77 such as caveolin 1 or flotillin 1 from lipid raft fractions in flotation assay (13). Furthermore, in 78 KO mice lacking both GD2/GM2 synthase and GD3 synthase, a GPI-anchored complement-79 regulatory protein CD55/decay-accelerating factor also disperses from lipid rafts, and unfavorable 80 activation of complement system occurs (12). Complement activation starts with the activation of 81
C1q by antigen-antibody complex or spontaneous hydrolysis of C3 and causes a cascade of further 82 cleavage and activation processes of complement proteins. Complement activation results in the 83 accumulation of complement proteins such as C1q or C3b and the formation of the membrane 84 attack complex. In the KO mice lacking both GD2/GM2 synthase and GD3 synthase, gene 85 expression of complement proteins such as C1qa, C3, or C4 was up-regulated, and deposition of 86 C1q in the brain increased (12, 13). Meanwhile, an activation of the complement system and 87 accumulation of C1q, C3, or membrane attack complex have also been demonstrated in brains of 88 human patients with prion diseases or prion-infected animals (14, 15). The role of complement 89 activation in prion disease pathogenesis has been proposed to cause degeneration of prion-90 infected neurons or to facilitate microglial phagocytosis of prion-infected neurons (15). 91
In this study, we performed a prion transmission study using various ganglioside synthase 92 knock-out mouse lines to investigate the role of gangliosides in the pathogenesis of prion diseases. 93
94

MATERIALS AND METHODS 95
Ethics statement 96
Animal experiments were performed in strict accordance with the Regulations for Animal 97 Generation of KO mice lacking GD2/GM2 synthase (B4GALNT1), GD3 synthase (ST8SIA1), or 105 GM3 synthase (ST3GAL5) have been reported previously (16, 17). These mice were backcrossed 106 to C57BL/6, and the resulting heterozygous animals were intercrossed to provide homozygous 107 KO mice and wild-type (WT) littermate controls. Thus, all of the KO mice and WT littermate 108 controls were on a C57BL/6 background. 109 110
Sources of inocula 111
A mouse-adapted scrapie prion strain Chandler (18) was kindly provided by Dr. Motohiro 112 Horiuchi. A mouse-adapted Gerstmann-Sträussler-Scheinker syndrome prion strain Fukuoka-1 113 (19) was maintained in C57BL/6 mice. The inocula were prepared from the brain of terminally ill 114 mice. 115
116
Transmission experiments 117
Intracerebral inoculation was performed as described (20). Briefly, 10% brain homogenates were 118 prepared in sterile phosphate-buffered saline using glass homogenizers, and 20 μl of the 119 homogenates were intracerebrally inoculated into mice (n = 6 or 7). The inoculated mice were 120 sacrificed at a predefined clinical endpoint, or at the time point showing intercurrent illness. One 121 hemisphere of the brain was fixed in 10% buffered formalin for histopathological analysis, and 122 the other hemisphere was immediately frozen for biochemical analysis. Formalin-fixed mouse brain tissues were treated with 60% formic acid for 1 hour to inactivate the 126 infectivity and embedded in paraffin. The embedded tissues were sectioned at a thickness of 5 127 µm. Tissue sections were pretreated by hydrolytic autoclaving before PrP immunohistochemistry 128 PrP Sc was purified from the mouse brain as described (23). Briefly, brain tissues were 138 homogenized in 2 ml of lysis buffer (100 mM Tris-HCl pH 8.0, 10 mM NaCl, 10 mM MgCl2, 2% 139 Triton X-100, and 25 units/ml DNase I (Takara Bio, Shiga, Japan)) and digested with collagenase 140 (1 mg/200 mg tissue) (FUJIFILM Wako Pure Chemical Corporation) overnight at room 141 temperature. Collagenase digestion disrupts the connective tissue and improves the accessibility 142 of detergents and/or proteinase K (PK) to PrP Sc (24). The digested homogenates were 143 ultracentrifuged at 453,000 g for 30 min at 4°C, and the pellets were resuspended and sonicated 144 in 870 μl of PK-digestion buffer (100 mM Tris-HCl pH 8.0 and 5% Sarkosyl (Sigma-Aldrich, St. 145 Louis, MO)). The resuspended samples were centrifuged at 10,000 g for 3 min to remove the cell 146 debris, and the supernatants (800 μl) were digested with PK (4 μg/200 mg tissue) (FUJIFILM 147 Wako Pure Chemical Corporation) for 1 h at 37°C. It has been reported that these conditions for 148 8 PK-digestion were sufficient for the complete digestion of normal PrP C , and that higher PK 149 concentrations caused unfavorable degradation of PrP Sc (25). The PK-digested proteins were 150 precipitated by adding 200 μl of 99.5% ethanol and ultracentrifugation at 135,000 g for 30 min at 151 4°C. The pellets were resuspended in 400 μl/200 mg tissue of Laemmli's sample buffer (60 mM 152
Tris-HCl pH 6.8, 5% glycerol, 2% SDS, and 0.01% bromophenol blue) and boiled at 100°C for 5 153 min. To examine the expression level of PrP C , C1qa, and β-actin, 10% homogenates were prepared 154 from uninfected mouse brains using the lysis buffer. The homogenates were boiled with the addition 155 of 0.25×volume of 5×Laemmli's sample buffer. 156 157
Flotation assay 158
To isolate lipid rafts, a flotation assay was performed as described previously (26). Briefly, 10% 159 homogenates were prepared from uninfected mouse brains using citrate buffer (20 mM sodium 160 citrate and 137 mM NaCl (pH 6.0)). The homogenates were centrifuged at 1,000 g for 5 min at 161 4°C to remove cell debris and nuclei. The supernatants were mixed with 1×volume of ice-cold 162
Brij O-10 extraction buffer (0.1% Brij O-10 (Sigma-Aldrich), 20 mM sodium citrate, and 137 163 mM NaCl (pH 6.0)) and incubated on a rocker at 4°C for 30 min, and then mixed with 1.4×volume 164 of 60% Optiprep (Axis-Shield, Dundee, UK). In 12 ml polycarbonate centrifuge tubes (Beckman 165
Coulter, Brea, CA), 9 ml of 0-30% Optiprep continuous gradients were prepared by Gradient 
Statistical analysis 201
The Kaplan-Meier log-rank test was used to analyze survival data in transmission study. Kramer test was used to analyze signal intensity data in western blot analysis. The statistical tests were 203 carried out using the statistical software EZR, version 1.36 (28). P < 0.05 was considered statistically 204 significant. 205 206 RESULTS 207
Transmission of prions to KO mice lacking ganglioside synthase gene 208
To investigate the role of gangliosides in the pathogenesis of prion diseases, we performed 209 intracerebral transmission study using KO mice lacking GD2/GM2 synthase (GD2/GM2 KO), 210 GD3 synthase (GD3 KO), or GM3 synthase (GM3 KO). These KO mice lack particular 211 ganglioside species depending on the ablated ganglioside synthase gene (Figure 1 ). For a mouse-212 adapted scrapie strain Chandler, the mean incubation time of GD2/GM2 KO mice (126.6±0.3 213 days) was reduced by 20% compared with that of WT mice (157.5±1.2 days, P < 0.01) (Figure  214 2). The mean incubation time of GM3 KO mice was also slightly reduced (149.5±2.2 days, P < 215 0.01). For a mouse-adapted Gerstmann-Sträussler-Scheinker syndrome strain Fukuoka-1, the 216 mean incubation time of GD2/GM2 KO mice and GM3 KO mice tended to be reduced compared 217 with that of WT mice, though the differences were not statistically significant. in the inoculated mice. Therefore, we next performed neuropathological analysis of the inoculated 222 mice to examine whether the strain characteristics were altered by the ablation of the ganglioside 223 synthase gene. In the Chandler-inoculated mice, spongiform changes were distributed through the 224 cerebral and cerebellar cortices, striatum, thalamus, hippocampus, pons, and cerebellar white 225 matter ( Figure 3A ). In the Fukuoka-1-inoculated mice, the vacuoles of spongiform changes 226 became larger and were distributed more intensively in the pons and cerebellar white matter 227 ( Figure 3B , C). There was no difference in the distribution of spongiform changes among mouse 228 lines ( Figure 3C ). However, in immunohistochemical analysis of disease-associated PrP, PrP TSE , 229 GD2/GM2 KO mice inoculated with the Chandler strain showed decreased PrP TSE deposition 230 ( Figures 3A, D) . In addition, Iba1-positive microglia and GFAP-positive astroglia were also fewer 231 in the Chandler-inoculated GD2/GM2 KO mice. For the Fukuoka-1 strain, GD2/GM2 KO mice 232 showed decreased microglial reaction, but PrP TSE deposition or astroglial reaction was not altered 233 ( Figures 3B, D) . Western blot analysis of PK-resistant PrP Sc in the brain revealed that the strain-specific 237 biochemical properties of PrP Sc , i.e., apparent molecular mass and patterns of N-linked 238 glycosylation, were not modified by the absence of ganglioside synthase genes ( Figure 4A ). The 239 apparent molecular mass of PrP Sc in the Chandler-inoculated mice was smaller than that in the 240 Fukuoka-1-inoculated mice, regardless of the mouse genotype. Meanwhile, the Chandler-241 inoculated GD2/GM2 KO mice showed slightly decreased PrP Sc accumulation compared with 242 WT, GD3 KO, or GM3 KO mice ( Figure 4A, B) . Of note, the apparent amount of PrP Sc in western 243 blot analysis did not reflect the degree of PrP TSE deposition in the immunohistochemical analysis. 244
For example, a GD2/GM2 KO mouse (#145) that showed reduced PrP TSE deposition in the 245 immunohistochemical analysis, i.e., score 1, had similar apparent amount of PrP Sc to that of 246 another GD2/GM2 KO mouse (#203) that showed abundant PrP TSE deposition in the 247 immunohistochemistry, i.e., score 3 ( Figure 4A ). Thus, GD2/GM2 KO showed shortened 248 incubation time, reduced PrP TSE deposition with attenuated glial reactions in neuropathological 249 analysis, and slightly decreased PK-resistant PrP Sc accumulation in western blot analysis. 250
In addition, we compared the amount of PrP C in the brain of uninfected KO mice 251 because the expression level of PrP C can directly affect the incubation period. However, the 252 amount of PrP C was not modified by the absence of ganglioside synthase genes ( Figure 4C) , 253
suggesting that the expression level of PrP C is unrelated to the changes in incubation period. 254 255
Evaluation of complement system 256
To gain insights into the shortened incubation period in GD2/GM2 KO mice, we then examined 257 the involvement of complement system because it has been reported that KO mice lacking both 258 GD2/GM2 synthase and GD3 synthase show dispersion of GPI-anchored complement-regulatory 259 proteins from lipid rafts and activation of the complement system (12, 13). To assess the activation 260 of the complement system, the amount of a complement factor C1qa in the brain was compared 261 between GD2/GM2 KO mice and WT mice by western blot analysis ( Figure 5 ). However, there 262 was no difference in C1qa level between GD2/GM2 KO mice and WT mice. C1qa accumulated 263 only in the prion-infected animals regardless of the mouse genotype or prion strain. In addition, 264 although dispersion of GPI-anchored complement-regulatory protein CD55 from lipid rafts has 265 been demonstrated in KO mice lacking both GD2/GM2 synthase and GD3 synthase, the floating 266 patterns of CD55 were not different between GD2/GM2 KO mice and WT mice in the flotation 267 assay of lipid raft-associated proteins in the brain ( Figure 6A ), suggesting that CD55 did not 268 13 disperse from lipid rafts in GD2/GM2 KO mice. Thus, the shortened incubation period in the 269 Chandler-inoculated GD2/GM2 KO mice was not due to altered activation of the complement 270 system. 271
272
Flotation assay of PrP C and lipid raft-associated proteins 273
We subsequently investigated whether PrP C and lipid raft-associated proteins other than CD55 274 disperse from lipid rafts in GD2/GM2 KO mice by flotation assay. As reported previously (13), a 275 lipid raft marker flotillin 1 dispersed from the lipid raft fractions (fractions 7-11) to the non-raft 276 fractions (fractions 15-18) in GD2/GM2 KO mice ( Figure 6B ). Furthermore, PrP C also dispersed 277 from the lipid raft fractions to the non-raft fractions in GD2/GM2 KO mice ( Figure 6C ). In 278 contrast, the floating patterns of a GPI-anchored PrP-associated calcium channel protein 279 CACNA2D1 (29,30) or those of a GPI-anchored protein Thy1 were not different between 280 GD2/GM2 KO mice and WT mice ( Figure 6D, E) . Thus, certain lipid raft-associated proteins 281
including PrP C dispersed from lipid rafts in the brain of GD2/GM2 KO mice. In addition, even in the Chandler-inoculated GD2/GM2 KO mouse group, the apparent amount 298 of PK-resistant PrP Sc did not reflect the PrP TSE deposition score in the immunohistochecmical 299 analysis. This finding raises a possibility that the amount of PK-sensitive PrP Sc (31-33) might 300 largely decrease in the Chandler-inoculated GD2/GM2 KO mice. Meanwhile, the incubation time 301 was shortened in the Chandler-inoculated GD2/GM2 KO mice in spite of the decreased PrP Sc 302 accumulation. To account for this discrepancy, further studies will be needed in the future 303 addressing the questions whether the dispersion of PrP Sc and/or PrP C from lipid rafts reduces the 304 formation of PK-sensitive PrP Sc or affects the neurotoxicity of PrP Sc . 305
There remains a possibility that the alteration in ganglioside composition might directly affect 306 the conformation of PrP. The ablation of ganglioside synthase causes massive alteration of 307 ganglioside composition (17). For example, an ablation of GD2/GM2 synthase causes depletion 308 of GD2, GM2 and downstream gangliosides such as GM1, and results in accumulation of GD3 309 and GM3 (16, 34). PrP C is co-localized and co-immunoprecipitated with GM1 and GM3 (35, 36). 310 GM1 binds to the C-terminus of PrP and modifies the conformational properties of PrP (37, 38). 311
Similarly, GM1 binds to amyloid β (Aβ) and modifies the conformation of Aβ, resulting in the 312 formation of endogenous seeds for amyloid fibril formation (39). Therefore, the direct effects of 313 gangliosides on PrP conformation are not negligible. To test this hypothesis, analysis of 314 conformational properties of PrP C and PrP Sc from GD2/GM2 KO mice will be needed in the future. 315 We cannot exclude a possibility that the alteration in ganglioside composition might affect the 316 15 activation of glial cells. Although the role of glial cells in the pathogenesis of prion diseases is 317 controversial, both microglia and astroglia are activated in prion diseases (40-43). The decreased 318 number of microglia and astroglia in the Chandler-inoculated GD2/GM2 KO mice might simply 319 reflect the decreased PrP TSE deposition. However, although the amount of PrP TSE deposition was 320 not altered, the Fukuoka-1-inoculated GD2/GM2 KO mice also showed attenuated microglial 321 reaction. Therefore, the altered ganglioside composition may affect glial reactions regardless of 322 the PrP TSE accumulation. Indeed, ethanol-induced astroglial activation is attenuated in GD2/GM2 323 KO mice (44). Further studies will be required to examine whether the shortened incubation time 324 in GD2/GM2 KO mice relates to the attenuated microglial reaction including neuroprotective 325 microglia (45, 46). 326
In conclusion, we have shown that the ablation of GD2/GM2 synthase gene causes a significant Fukuoka-1-inoculated mice. There was no difference in the biochemical properties of PK-491 resistant PrP Sc among mouse lines. The Chandler-inoculated mice consistently produced lower 492 apparent molecular mass of unglycosylated PrP Sc fragments compared with those of the Fukuoka-493 1-inoculated mice regardless of their genotype. The Chandler-inoculated GD2/GM2 KO mice 494 showed slightly decreased apparent amount of PrP Sc compared with WT, GD3 KO, or GM3 KO 495 mice, irrespective of the degree of PrP TSE deposition in the immunohistochemical analysis. For 496 example, a GD2/GM2 KO mouse (#145) that showed reduced PrP TSE deposition in the 497 immunohistochemical analysis, i.e., score 1, had similar apparent amount of PK-resistant PrP Sc 498 compared with that of another GD2/GM2 KO mouse (#203) that showed abundant PrP TSE 499 deposition in the immunohistochemistry, i.e., score 3. A brain sample, equivalent to 125 μg in wet 
